In 2025, we achieved 10x growth in patients enrolled. Here's what actually moved the needle — and what we learned along the way.
More articles
15 strategies that appear across well-run recruitment programs — with context on when each tends to be most useful across the enrollment lifecycle.
There's a pattern we keep seeing across sites — a two-call workflow that's costing more patients than most coordinators realize.
What a nearly-pathologist turned neuroscience CMO learned about humility, endpoints, and following the science wherever it leads.
Not every enrollment slowdown is a site problem. Sometimes it's a portfolio problem. Here's how to tell the difference and what to do about it.
How a workflow change (not a bigger patient list) has already helped one site double their screening visit bookings.
What a compressed-timeline recruitment test revealed about execution at scale.
Your local call center knows exactly how every agent performed today. Your clinical trial sites? They're still filling out spreadsheets.
From brain circuit research at Stanford to building the operational infrastructure for precision psychiatry at scale.
How Joseph Palumbo went from a failed ALS program in 1996 to leading the first new ALS approval in two decades — and what patient selection had to do with it.
Same protocol. Same criteria. Different phrasing. Why your top sites convert 3x better — and how to find out what they're doing.
Most sponsors are flying blind between monthly reports while their sites are silently drowning. Here's how to catch problems in week 1 instead of week 10.
In 2025, we achieved 10x growth in patients enrolled. Here's what actually moved the needle — and what we learned along the way.
Strong start, steady month 2, then plateau. By month 3, enrollment rates drop 32% on average — and rarely recover. Here's why, and what to do about it.
Why patients who seem "engaged" disappear — and what site behaviors may be driving them away.
Great science means little without flawless execution. Here's what operational discipline looks like when it accelerates a regulatory timeline by nine to twelve months.
The AtaiBeckley merger reflects a bet that shorter treatment durations will improve patient access and payer acceptance.
72% of potential trial participants who call a site never make it to a screening visit. The gap between 'interested patient' and 'scheduled screening' is costing you enrollment.
What happens when a qualified patient is ready to engage... and nobody's available to respond? The case for rethinking your pre-screening model.
Why smart clin ops teams focus on practical AI wins instead of chasing shiny objects.